Molina Healthcare에 대한 매도 수량은 투자자에게 Molina Healthcare의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Molina Healthcare (NYSE:MOH) 주식, 공매도 수량 보고

Molina Healthcare

Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.

Asia

Equities

News

Global

Markets

ACIC

AMZN

BABA

BCAB

BIDU

FOUR

GOOG

GOOGL

OLPX

REAL

2008년 금융 위기 이전 주택 시장에 대한 선견지명 있는 투자로 유명한 유명 투자자 마이클 버리(Michael Burry)는 2024년 2분기에 자신의 헤지 펀드 포트폴리오에 큰 변화를 주었다.

&#39;빅쇼트&#39; 명성의 마이클 버리, 중국에 큰 투자하고 알리바바를 최대 보유 주식으로 공개

Movers

AVTR

CBRE

ENPH

FCNCA

LPLA

MANH

SIRI

SPOT

이들 11개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? QXO(NASDAQ:QXO)의 주가는 사모 금융 유치를 발표한 이후 33.37% 상승했다.

유니버셜 헬스 및 록히드 마틴은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (7월 21일-7월 27일)

Molina Healthcare Inc

MOTOR OIL HELLAS CORINTH by Motor Oil (Hellas) Corinth Refineries S.A.

Motor Oil (Hellas) Corinth Refineries SA

MOTOR OIL HELLAS UNSP/ADR by Motor Oil (Hellas) Corinth Refineries S.A.

ECMOHO Ltd

Collaborative Investment Series Trust Mohr Growth ETF

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 10 years by 12.09% on an annualized basis producing an average annual return of 23.31%. Currently, Molina Healthcare has a market capitalization of $20.58 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 10 years ago, it would be worth $791.70 today based on a price of $351.12 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1726862566_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 10 Years

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has been analyzed by 13 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $368.69, a high estimate of $406.00, and a low estimate of $297.00. Observing a downward trend, the current average is 3.46% lower than the prior average price target of $381.92. 
<img src="https://www.benzinga.com/files/images/story/2024/1725998420_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The perception of Molina Healthcare by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$360.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>George Hill</td>
<td>Deutsche Bank</td>
<td>Lowers</td>
<td>Hold</td>
<td>$353.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$378.00</td>
<td>$351.00</td>
</tr>
<tr>
<td>Scott Fidel</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$320.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Gary Taylor</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$351.00</td>
<td>$412.00</td>
</tr>
<tr>
<td>David Windley</td>
<td>Jefferies</td>
<td>Lowers</td>
<td>Hold</td>
<td>$297.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$406.00</td>
<td>$406.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$315.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$400.00</td>
<td>$440.00</td>
</tr>
<tr>
<td>Lisa Gill</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$395.00</td>
<td>$420.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Molina Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Molina Healthcare compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Molina Healthcare's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Molina Healthcare's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/MOH/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Molina Healthcare analyst ratings.</a>
<h2>Get to Know Molina Healthcare Better</h2>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Financial Insights: Molina Healthcare</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Molina Healthcare's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 18.65% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Molina Healthcare's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 3.05%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Molina Healthcare's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 6.45%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Molina Healthcare's ROA stands out, surpassing industry averages. With an impressive ROA of 1.96%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Molina Healthcare's debt-to-equity ratio is below the industry average at 0.49, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Expert Ratings For Molina Healthcare

Cantor Fitzgerald analyst Sarah James reiterates Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Overweight and maintains $406 price target.

Price Target

Reiteration

Cantor Fitzgerald Reiterates Overweight on Molina Healthcare, Maintains $406 Price Target

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 16.12% since its last report. The company recently reported that it has 1.58 million shares sold short, which is 3.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725976812_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 3.65%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Peering Into Molina Healthcare's Recent Short Interest

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 15 years by 11.8% on an annualized basis producing an average annual return of 23.48%. Currently, Molina Healthcare has a market capitalization of $20.70 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 15 years ago, it would be worth $24,065.93 today based on a price of $353.21 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1725478210_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Molina Healthcare Stock In The Last 15 Years

Investors in Molina Healthcare, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/moh#NYSE">MOH</a>) need to pay close attention to the stock based on moves in the options market lately. That is because the Sep 20, 2024 $270.00 Call had some of the highest implied volatility of all equity options today.
<h2>What is Implied Volatility?</h2>
Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction or the other. It could also mean there is an event coming up soon that may cause a big rally or a huge sell-off. However, implied volatility is only one piece of the puzzle when putting together an options trading strategy.
<h2>What do the Analysts Think?</h2>
Clearly, options traders are pricing in a big move for Molina Healthcare shares, but what is the fundamental picture for the company? Currently, Molina Healthcare is a Zacks Rank #3 (Hold) in the Medical - HMOs industry that ranks in the Bottom 10% of our Zacks Industry Rank. Over the last 30 days, one analyst has increased the earnings estimates for the current quarter, while four have dropped their estimates. The net effect has taken our Zacks Consensus Estimate for the current quarter from earnings of $5.95 per share to $6.02 in that period.
Given the way analysts feel about Molina Healthcare right now, this huge implied volatility could mean there&#39;s a trade developing. Oftentimes, options traders look for options with high levels of implied volatility to sell premium. This is a strategy many seasoned traders use because it captures decay. At expiration, the hope for these traders is that the underlying stock does not move as much as originally expected.
<a href="https://www.zacks.com/stock/news/2327124/do-options-traders-know-something-about-molina-healthcare-moh-stock-we-don-t?cid=CS-BENZ-FT-tale_of_the_tape|options-2327124">To read this article on Zacks.com click here.</a>

Earnings

Large Cap

Health Care

Options

General

Do Options Traders Know Something About Molina Healthcare Stock We Don't?

Molina Healthcare's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) short percent of float has fallen 16.12% since its last report. The company recently reported that it has 1.58 million shares sold short, which is 3.07% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Molina Healthcare Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724253315_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Molina Healthcare has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Molina Healthcare's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Molina Healthcare's peer group average for short interest as a percentage of float is 4.21%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Looking Into Molina Healthcare's Recent Short Interest

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 20 years by 6.84% on an annualized basis producing an average annual return of 15.24%. Currently, Molina Healthcare has a market capitalization of $20.51 billion. 
Buying $1000 In MOH: If an investor had bought $1000 of MOH stock 20 years ago, it would be worth $16,747.68 today based on a price of $349.97 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1724090416_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 20 Years Ago, You Would Have $17,000 Today

Famed investor Michael Burry, known for his prescient bet against the housing market before the 2008 financial crisis, has made significant changes to his hedge fund&#8217;s portfolio in the second quarter of 2024. 
What Happened: Scion Asset Management, based in Saratoga and run by Burry, filed its latest 13F report with the U.S. Securities and Exchange Commission on Wednesday, revealing a notable shift in investment strategy.
Key Highlights:
<ol>
<li>Alibaba Group Holding Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) Takes Top Spot: Chinese e-commerce giant Alibaba has become Scion&#8217;s largest holding, with a position valued at approximately $11.16 million, consisting of 155,000 shares.</li>
<li>Tech Focus: The portfolio shows a continued interest in Chinese tech companies, with significant positions in Baidu Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) with 75,000 shares valued at $6.49 million, and JD.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with 250,000 shares valued at $6.46 million.</li>
<li>Healthcare and Fintech: Molina Healthcare Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) and Shift4 Payments Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FOUR#NYSE">FOUR</a>) represent substantial investments, valued at $7.29 million and $7.34 million respectively.</li>
<li>Real Estate Exposure: Hudson Pacific Properties Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPP#NYSE">HPP</a>) stands out as a significant real estate play, with over 1.1 million shares valued at $5.50 million.</li>
<li>Emerging Biotech: BioAtla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCAB#NASDAQ">BCAB</a>), a clinical-stage biopharmaceutical company, represents a smaller but noteworthy position in the portfolio.</li>
</ol>
Other notable holdings include The RealReal Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>), Olaplex Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLPX#NASDAQ">OLPX</a>), and American Coastal Insurance Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>).
See Also: <a href="https://www.benzinga.com/markets/equities/24/08/40329069/cathie-wood-seizing-low-valuation-opportunity-among-magnificent-7-ark-invest-snaps-up-2-4m-in-al?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Cathie Wood Seizing Low-Valuation Opportunity Among Magnificent 7? Ark Invest Snaps Up $2.4M In Alphabet Shares</a>
Why It Matters: This latest filing offers insight into Burry&#8217;s current market outlook, suggesting a diverse approach with significant bets on Chinese technology firms, U.S. healthcare, fintech, and select real estate opportunities. 
In May, Burry made headlines for his substantial investments in <a href="https://www.benzinga.com/markets/asia/24/05/38878116/big-short-investor-michael-burry-bets-heavy-on-gold-renewable-energy-stocks-exits-amazon-alphabet">gold and renewable energy</a>, while exiting positions in major tech companies like Amazon.com Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>). This pivot indicated a focus on physical commodities and sustainable energy sources.
In a related development, a <a href="https://www.benzinga.com/general/entertainment/24/07/39695004/elon-musk-warren-buffett-nancy-pelosi-jensen-huang-michael-saylor-who-you-sitting-by-on-a-p">recent poll highlighted </a>how investors seek advice from top figures like Elon Musk, Warren Buffett, and Burry himself, underscoring his influence in the investment community.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/08/40303410/warren-buffett-declares-shift-selling-apple-stock-to-invest-in-this-magnificent-megacap-heres-why?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Warren Buffett Declares Shift: Selling Apple Stock To Invest In This &#8216;Magnificent&#8217; Megacap – Here&#8217;s Why</a></li>
</ul>
Michael Burry illustration by Gonzalo Lanzilotta for
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

'Big Short' Fame Michael Burry Bets Big On China, Reveals Alibaba As Top Holding — JD.com And Baidu Also Feature On Scion's Portfolio

Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) has outperformed the market over the past 10 years by 12.81% on an annualized basis producing an average annual return of 23.34%. Currently, Molina Healthcare has a market capitalization of $19.74 billion. 
Buying $100 In MOH: If an investor had bought $100 of MOH stock 10 years ago, it would be worth $830.16 today based on a price of $336.88 for MOH at the time of writing.
<h3>Molina Healthcare's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1723150830_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Wells Fargo analyst Stephen Baxter maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and raises the price target from $315 to $360.

Wells Fargo Maintains Equal-Weight on Molina Healthcare, Raises Price Target to $360

Revealing a significant insider sell on July 30, Jeff D Barlow, Chief Legal Officer at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), as per the latest SEC filing.
What Happened: Barlow's decision to sell 5,340 shares of Molina Healthcare was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992924000126//Archives/edgar/data/1179929/000117992924000126/0001179929-24-000126-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the sale is $1,788,900.
At Wednesday morning, Molina Healthcare shares are down by 1.13%, trading at $346.76.
<h3>Get to Know Molina Healthcare Better</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Financial Milestones: Molina Healthcare's Journey</h3>
Revenue Growth: Over the 3 months period, Molina Healthcare showcased positive performance, achieving a revenue growth rate of 18.65% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Profitability Metrics:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 12.29%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 5.18.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio surpasses industry norms, standing at 0.49. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
Navigating Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 19.24, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.55 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 8.32, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Activity Matters in Finance</h3>
Insider transactions contribute to decision-making but should be supplemented by a comprehensive investment analysis.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes To Focus On</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Molina Healthcare Chief Legal Officer Trades $1.79M In Company Stock

A substantial insider sell was reported on July 30, by Steven J Orlando, Board Member at Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>), based on the recent SEC filing.
What Happened: Orlando's recent move involves selling 1,000 shares of Molina Healthcare. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001179929/000117992924000127//Archives/edgar/data/1179929/000117992924000127/0001179929-24-000127-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value is $339,210.
The latest update on Wednesday morning shows Molina Healthcare shares down by 1.64%, trading at $344.99.
<h3>Unveiling the Story Behind Molina Healthcare</h3>
Molina Healthcare Inc offers healthcare plans focused on Medicaid-related solutions for low-income families and individuals. Its health plans are operated by a network of subsidiaries, each of which is licensed as a health maintenance organization (HMO). It has four segments: Medicaid, Medicare, Marketplace and Others. The Medicaid, Medicare, and Marketplace segments represent the government-funded or sponsored programs under which it offers managed healthcare services. The Other segment, which is insignificant to its consolidated results of operations, includes long-term services and supports consultative services in Wisconsin. It generates majority revenue from Medicaid segment.
<h3>Molina Healthcare: Delving into Financials</h3>
Revenue Growth: Molina Healthcare displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 18.65%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Evaluating Earnings Performance:
<ul>
<li>
Gross Margin: The company issues a cost efficiency warning with a low gross margin of 12.29%, indicating potential difficulties in maintaining profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Molina Healthcare's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 5.18.
</li>
</ul>
Debt Management: Molina Healthcare's debt-to-equity ratio stands notably higher than the industry average, reaching 0.49. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 19.24 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 0.55 is lower than the industry average, implying a discounted valuation for Molina Healthcare's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 8.32 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Exploring the Significance of Insider Trading</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Navigating the World of Insider Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001179929">Check Out The Full List Of Molina Healthcare's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Unloading: Steven J Orlando Sells $339K Worth Of Molina Healthcare Shares

Deutsche Bank analyst George Hill maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Hold and lowers the price target from $354 to $353.

Deutsche Bank Maintains Hold on Molina Healthcare, Lowers Price Target to $353

TD Cowen analyst Gary Taylor maintains Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Buy and raises the price target from $351 to $378.

TD Cowen Maintains Buy on Molina Healthcare, Raises Price Target to $378

These eleven large-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>QXO, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QXO#NASDAQ">QXO</a>) shares escalated 33.37% after the company announced <a href="https://www.benzinga.com//node/39880836" target="_blank" rel="noreferrer noopener">a private placement financing</a>.</li>
<li>Avantor Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) stock gained 21.62% in the last week after it was announced the stock will join the S&amp;P MidCap 400. Also, it reported better-than-expected Q2 earnings.</li>
<li>Universal Health Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UHS#NYSE">UHS</a>) stock jumped 17.73% after the company reported better-than-expected&nbsp;Q2&nbsp;earnings and <a href="https://www.benzinga.com//node/39942622" target="_blank" rel="noreferrer noopener">increased FY 2024&nbsp;guidance</a>.</li>
<li>Manhattan Associates Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) stock upped 17.02% after reporting better-than-expected Q2 financial results. Several analysts raised their <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecasts on the stock</a>.</li>
<li>Molina Healthcare Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) shares increased 15.53% following <a href="https://www.benzinga.com//node/39942485" target="_blank" rel="noreferrer noopener">better-than-expected&nbsp;Q2&nbsp;earnings</a>.</li>
<li>First Citizens BancShares, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCNCA#NASDAQ">FCNCA</a>) shares increased 15.15% after the company reported better-than-expected earnings.</li>
<li>Tenet Healthcare Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>) stock increased 13.02% after the company reported better-than-expected&nbsp;Q2&nbsp;financial results, and the company raised its FY24&nbsp;guidance&nbsp;above estimates and issued&nbsp;Q3&nbsp;guidance&nbsp;above estimates. Also, the company announced it a<a href="https://www.benzinga.com//node/39934114" target="_blank" rel="noreferrer noopener">uthorized a&nbsp;$1.5 billion&nbsp;share buyback</a>.</li>
<li>CBRE Group Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NYSE">CBRE</a>) shares gained 12.99% in the last week after the company raised its 2024 guidance. Several analysts raised their <a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">price forecasts on </a><a href="https://www.benzinga.com/quote/CBRE/analyst-ratings" target="_blank" rel="noreferrer noopener">t</a><a href="https://www.benzinga.com/quote/MANH/analyst-ratings" target="_blank" rel="noreferrer noopener">he stock</a>.</li>
<li>Thermo Fisher Scientific Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) stock rose 12.63% in the last week. The company raised <a href="https://www.benzinga.com//node/39930516" target="_blank" rel="noreferrer noopener">its annual outlook</a>.</li>
<li>Danaher Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) stock gained 11.30% are trading higher after the company reported better-than-expected Q2 earnings.</li>
<li>Lockheed Martin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) stock grew 10.72% on positive analyst <a href="https://www.benzinga.com//node/39941283" target="_blank" rel="noreferrer noopener">ratings and strong Q2 results</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/24/07/40001668/ford-stellantis-and-dell-are-among-top-12-large-cap-losers-last-week-july-21-july-27-are-the-other">Ford, Stellantis And Dell Are Among Top 12 Large Cap Losers Last Week (July 21-July 27): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Universal Health Services & Lockheed Martin Were Among Top 11 Large Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?

Stephens &amp; Co. analyst Scott Fidel reiterates Molina Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) with a Equal-Weight and maintains $320 price target.

Stephens & Co. Reiterates Equal-Weight on Molina Healthcare, Maintains $320 Price Target

U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining over 350 points on Thursday.
The Dow traded up 0.91% to 40,215.50 while the NASDAQ rose 0.59% to 17,444.67. The S&amp;P 500 also rose, gaining, 0.57% to 5,458.21.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39957788/jim-cramer-this-tech-stock-is-absolutely-terrific-but-jumia-its-not-making-a-lot-of-mone"> Jim Cramer: This Tech Stock Is &#8216;Absolutely Terrific,&#8217; But Jumia? It&#8217;s Not Making A Lot Of Money </a>
Leading and Lagging Sectors Industrials shares jumped by 1.8% on Wednesday.
In trading on Wednesday, utilities shares fell by 0.8%.
Top Headline
Northrop Grumman Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOC#NYSE">NOC</a>) reported better-than-expected second-quarter earnings and raised its guidance.
Northrop Grumman reported second-quarter fiscal 2024 sales growth of 7% year-over-year to $10.218 billion, beating the consensus of $10.018 billion. Second-quarter EPS was $6.36 compared to $5.34 a year ago, beating the consensus of $5.92.
For fiscal 2024, Northrop Grumman now expects sales of $41 billion-$41.4 billion (from $40.8 billion – $41.2 billion) versus the consensus of $41.139 billion.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Goosehead Insurance, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) shares shot up 29% to $84.82 following upbeat second-quarter results.</li>
<li>Shares of Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) got a boost, surging 15% to $331.04 following better-than-expected quarterly earnings.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares were also up, gaining 30% to $65.44 after the company reported better-than-expected second-quarter EPS results. The company also announced the advancement of VK2735 to Phase 3.</li>
</ul>
Equities Trading DOWN
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares dropped 62% to $1.5799 after the company filed for Chapter 11 bankruptcy to facilitate a Restructuring Support Agreement.</li>
<li>Shares of Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) were down 29% to $61.41 after the company reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired JenaValve and Endotronix.</li>
<li>MaxLinear, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NASDAQ">MXL</a>) was down, falling 31% to $15.41 after the company reported worse-than-expected second-quarter financial results.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/news/24/07/39958830/top-3-defensive-stocks-that-are-ticking-portfolio-bombs">Top 3 Defensive Stocks That Are Ticking Portfolio Bombs</a>
Commodities In commodity news, oil traded up 0.9% to $78.32 while gold traded down 2.5% at $2,354.80.
Silver traded down 4.6% to $27.955 on Thursday, while copper rose 0.3% to $4.1215.
Euro zone
European shares were mixed today. The eurozone's STOXX 600 fell 0.72%, Germany's DAX fell 0.48% and France's CAC 40 fell 1.15%. Spain's IBEX 35 Index fell 0.58%, while London's FTSE 100 rose 0.40%.
Bank lending to households in the Eurozone rose by 0.3% year-over-year to €6.879 trillion in June. The Ifo Business Climate indicator for Germany fell for a third straight month to a reading of 87 in July from 88.6 in June. The manufacturing climate indicator in France declined to 95.5 in July from 98.9 in the prior month.
Asia Pacific Markets
Asian markets closed lower on Thursday, with Japan's Nikkei 225 falling 3.28%, Hong Kong's Hang Seng Index falling 1.77%, China's Shanghai Composite Index declining 0.52% and India's S&amp;P BSE Sensex declining 0.14%.
Imports to Hong Kong climbed 9% year-over-year to $429.2 billion, while exports from Hong Kong gained 10.7% to $373.5 billion in June. The People's Bank of China cut its one-year policy loan rate.
Economics
<ul>
<li>U.S. initial jobless claims declined by 10,000 to 235,000 in the week ending July 20, compared to market estimates of 238,000.</li>
<li>U.S. durable goods orders fell by 6.6% month-over-month in June.</li>
<li>The US economy grew by an annualized 2.8% in the second quarter, up from 1.4% in the prior quarter, and higher than expectations of 2%.</li>
<li>The EIA said U.S. natural-gas stocks increased 22 billion cubic feet during the week ended July 19, higher than market estimates of a 15 billion cubic feet gain.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39958828/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-6-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 6% Dividend Yields</a><a href="https://www.benzinga.com/news/24/07/39958828/wall-streets-most-accurate-analysts-weigh-in-on-3-energy-stocks-with-over-6-dividend-yields"> </a></li>
</ul>

Eurozone

Commodities

Intraday Update

GSHD

TWOU

VKTX

Gold Down 2.5%; Northrop Grumman Posts Upbeat Earnings

Shares of Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) fell sharply during Thursday's session after the company reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired <a href="https://www.benzinga.com/quote/EW/earnings">JenaValve and Endotronix</a>.
Edwards Lifesciences reported quarterly earnings of 70 cents per share which beat the analyst consensus estimate of 69 cents per share. The company reported quarterly sales of $1.632 billion which missed the analyst consensus estimate of $1.653 billion.
Edwards Lifesciences shares dipped 26.9% to $63.60 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) shares jumped 85% to $1.96 after the company entered biomarker discovery market after successful retrospective ovarian cancer study yields compelling results.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) rose 65.4% to $0.6424 after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.</li>
<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) jumped 60% to $3.4421.</li>
<li>Goosehead Insurance, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) rose 29.8% to $85.25 following upbeat second-quarter results.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares gained 28.2% to $64.64 after the company reported better-than-expected second-quarter EPS results.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) rose 27% to $0.5090.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) gained 25.4% to $0.2645 after gaining around 8% on Wednesday.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) rose 25.2% to $16.72. The company announced the successful completion of its first five commercial satellites.</li>
<li>Bally&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) gained 24.2% to $16.80. Bally&#8217;s entered into merger agreement with affiliates of Standard General L.P.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) climbed 18.3% to $341.39 following better-than-expected quarterly earnings.</li>
<li>The Shyft Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHYF#NASDAQ">SHYF</a>) gained 16.4% to $13.55 following upbeat earnings.</li>
<li>Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) climbed 16.3% to $141.59 after the company reported better-than-expected quarterly financial results.</li>
<li>Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) rose 15.4% to $12.56 after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares climbed 15.4% to $0.3499.</li>
<li>RPC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RES#NYSE">RES</a>) gained 15.1% to $6.64 following upbeat earnings.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) jumped 13.7% to $831.97 after the company reported better-than-expected second-quarter financial results.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) rose 13.1% to $69.09 after the company reported better-than-expected second-quarter financial results.</li>
<li>Helmerich &amp; Payne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) climbed 12.5% to $42.46 following third-quarter results.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) gained 12.2% to $2.75 after dipping 43% on Wednesday. BloomZ recently priced its IPO at $4.30 per share.</li>
<li>Valmont Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) gained 11.1% to $300.96 following upbeat earnings.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 10.5% to $128.36 following upbeat earnings.</li>
<li>Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) rose 10.1% to $53.92 following second-quarter results.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) gained 9.6% to $565.64 after the company reported better-than-expected second-quarter adjusted EPS and sales.</li>
<li>Mr. Cooper Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NYSE">COOP</a>) rose 9.5% to $94.86 following second-quarter results.</li>
<li>Oceaneering International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) gained 9.2% to $27.79 following strong sales.</li>
<li>RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) surged 8% to $113.24 following a second-quarter earnings beat.</li>
<li>J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) gained 6.1% to $173.75.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares dipped 60% to $1.65. 2U announced a strategic agreement with debtholders to eliminate half of debt and infuse $110 million in new capital.</li>
<li>EZFill Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZFL#NASDAQ">EZFL</a>) tumbled 40.3% to $3.73.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) fell 37.5% to $2.04 after the company submitted comment to the Department of Justice regarding cannabis rescheduling.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) dipped 34% to $0.3185. Cheetah Net Supply Chain Service announced pricing of $1.49 million follow-on public offering.</li>
<li>MaxLinear, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NYSE">MXL</a>) shares fell 30.7% to $15.45 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Sol-Gel Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) dipped 30% to $0.4750. Sol-Gel announced the signing of six exclusive license agreements to commercialize TWYNEO&#xAE; and EPSOLAY&#xAE; in Europe and South Africa.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 29.7% to $9.49 after declining 10% on Wednesday.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) fell 27% to $0.1159.</li>
<li>Orion Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) declined 21.9% to $8.62 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Ostin Technology Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares declined 20.3% to $0.35 after gaining around 19% on Wednesday.</li>
<li>Ribbon Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) tumbled 19.2% to $3.1450 after the company reported worse-than-expected quarterly revenue.</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares fell 16.6% to $11.40 following a second-quarter earnings miss.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) fell 15.1% to $0.9103. Hoth Therapeutics shares gained around 11% on Wednesday after the company signed an agreement with LTS Therapy Systems to develop and manufacture the HT-ALZ oral film prototype for Alzheimer&#8217;s disease.</li>
<li>Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) declined 13.8% to $7.86 after the company reported worse-than-expected quarterly financial results and lowered its FY24 guidance.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares fell 13.4% to $0.0396 after jumping over 75% on Wednesday.</li>
<li>Kaiser Aluminum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALU#NASDAQ">KALU</a>) declined 13.3% to $79.76 after the company reported worse-than-expected quarterly financial results.</li>
<li>Hut 8 Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NYSE">HUT</a>) declined 12.8% to $15.71.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) fell 12.1% to $39.10 after the company reported worse-than-expected quarterly adjusted EPS and sales. Additionally, the company lowered its FY24 adjusted EPS outlook.</li>
<li>STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) shares fell 12% to $34.81 after the company reported a second-quarter EPS miss and issued soft third-quarter guidance.</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) dipped 9.7% to $129.30 following soft third-quarter guidance.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) fell 9.5% to $292.91 after the company reported a quarterly earnings miss and cut its guidance.</li>
<li>FormFactor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) fell 8.2% to $52.26.</li>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) tumbled 8.2% to $249.52 after Citigroup downgraded the stock from a Buy to a Neutral and lowered its price target from $415 to $300.</li>
<li>Robert Half Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) declined 7% to $60.32 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) fell 6.8% to $18.27 following H1 results.</li>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares fell 6.2% to $7.01 after the company reported worse-than-expected EPS results.</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) declined 4.1% to $204.82 after the company lowered FY24 EPS guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39961297/this-lululemon-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday">This Lululemon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday</a></li>
</ul>

ASTS

ATPC

BALY

BLMZ

CERO

COOP

CTNT

EZFL

FORM

HOTH

INDV

JBHT

KALU

KDLY

LULU

PEGA

PLXS

POAI

RBBN

SHYF

SLGL

SLNA

SLRX

STLA

TIVC

XCUR

Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session

Does August's Rollercoaster Change Anything For Stocks?

An announcement from Molina Healthcare (MOH) is now available. Molina Healthcare, Inc. has made a strategic move to secure the leadership of Joseph...

Molina Healthcare Incentivizes CEO for Long-Term Leadership

Molina CEO Zubretsky to stay on through end of 2027

Molina CEO Zubretsky to stay on through the end of 2027

In a report released yesterday, Steve Baxter from Wells Fargo maintained a Hold rating on Molina Healthcare (MOH – Research Report), with a price t...

Wells Fargo Sticks to Their Hold Rating for Molina Healthcare (MOH)

Centene stock drops 8% amid lowered Medicaid forecast

Fidelity Growth Strategies Fund Q2 2024 Review

FOMC Preview: How Might Markets React After The Widely Expected Rate Cut

IHF: Healthcare Dashboard For September

TCW Relative Value Mid Cap Fund Q2 2024 Commentary

ACGL

ACGLN

ACGLO

ACHC

AKAM

ALGN

ALKS

ALLY

APOS

COLL

COST

CPAY

CVNA

DXCM

EXEL

FBCG

FBCV

FBND

FBTC

FCLD

FCOM

FCOR

FCPI

FDHY

FDIG

FDIS

FDLO

FDMO

FDRR

FDVV

FENY

FETH

FHLC

FIDI

FIDU

FLEX

FMAG

FMAT

FMET

FNCL

FQAL

FREL

FSMD

FSTA

FTEC

FUTY

FVAL

GEHC

HBAN

HBANL

HBANM

HBANP

HRMY

IDXX

INVA

MSCI

ONEQ

PLTR

PODD

RIVN

SBUX

TSLA

VEEV

Press Releases

Molina Healthcare Wins Michigan Medicaid Contract

Molina Healthcare Reports First Quarter 2024 Financial Results

Molina Healthcare of Wisconsin Receives Notice of Intent to Award New Region 5 Contract

Molina Healthcare Announces Second Quarter 2024 Earnings Release and Conference Call Dates

Molina Healthcare Awarded New Florida Medicaid Contract

Comments

Molina Healthcare

매도 수량

Molina Healthcare (NYSE:MOH) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌